Masimo (MASI)
(Delayed Data from NSDQ)
$108.09 USD
-0.90 (-0.83%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $108.05 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.09 USD
-0.90 (-0.83%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $108.05 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Zacks News
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.
Masimo (MASI) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Masimo (MASI) PVi Achieves Acceptable Fluid Response in Study
by Zacks Equity Research
Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.
Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.
Masimo (MASI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 12.82% and 2.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Analysts Estimate Masimo (MASI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) Patient Monitoring Devices Favored by New Study
by Zacks Equity Research
Masimo's (MASI) patient monitoring devices continue to aid researchers in their assessment of different ventilatory strategies for brain oxygenation during thoracoscopic surgery.
Masimo (MASI) Expands Partnership with Philips for W1 Watch
by Zacks Equity Research
Masimo (MASI) and Royal Philips to create an open ecosystem of medical information using Masimo W1 watch and the latter???s patient monitoring ecosystem to improve home-care.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit
by Zacks Equity Research
A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.
UnitedHealth's (UNH) UnitedHealthcare Unit to Aid Q4 Earnings?
by Zacks Equity Research
An increase in the number of people served in the commercial domestic business of UnitedHealth's (UNH) UnitedHealthcare segment is likely to boost fourth-quarter results.
UnitedHealth (UNH) to Post Q4 Earnings: What You Should Know
by Zacks Equity Research
UnitedHealth Group's (UNH) fourth-quarter results are likely to reflect growing premiums, products and higher expenses.
Masimo's (MASI) SpHb During Elective CS Favored by New Study
by Zacks Equity Research
Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.
3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.
Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome
by Zacks Equity Research
Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.
Masimo (MASI) Announces Positive Study Results on PBM by SpHb
by Zacks Equity Research
Masimo's (MASI) SpHb is likely to enhance transfusion management and post-operative patient outcomes on patients.
Masimo (MASI) Q3 Earnings Top Estimates, 2022 View Revised
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q3 sales.
Masimo (MASI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 8.70% and 2.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Why Masimo (MASI) Might Surprise This Earnings Season
by Zacks Equity Research
Masimo (MASI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business and informatics franchise.